Protego Biopharma raised $130 million to advance PROT-001 into a pivotal clinical trial for AL amyloidosis, a rare and often fatal protein misfolding disorder that leads to progressive organ damage, particularly in the heart.
Protego Biopharma raised $130 million to advance PROT-001 into a pivotal clinical trial for AL amyloidosis, a rare and often fatal protein misfolding disorder that leads to progressive organ damage, particularly in the heart.